Bullous pemphigoid (BP) is most often a disease of older adults—patients who frequently carry multiple comorbidities and have limited tolerance for broad immunosuppression. For years, systemic corticosteroids remained the mainstay of treatment, despite well-known safety concerns in this vulnerable population.
In this video, Prince Adotama, MD, Assistant Professor at NYU Grossman School of Medicine, shares clinical perspectives on how BP presents in real-world practice and how newer targeted options are changing the treatment landscape. From recognizing nonclassic presentations to navigating emerging therapies, Dr Adotama walks through key considerations for safely managing BP today.